A Randomized, Open-label Phase Ib Trial of Fruquintinib "4mg Once Daily Continuous" Versus "5mg Once Daily 3wks on/1wk Off " in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy

Trial Profile

A Randomized, Open-label Phase Ib Trial of Fruquintinib "4mg Once Daily Continuous" Versus "5mg Once Daily 3wks on/1wk Off " in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2014

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 10 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Jun 2014 Results for the first stage presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top